Page 19 - Cll News Today

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.

A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and second-line treatment regimens.

Alexey Danilov, MD, PhD, discusses how further research, including the development of NX-2127, may address unmet needs related to disease progression in patients with chronic lymphocytic leukemia or mantle cell lymphoma.

Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

Chaitra S. Ujjani, MD examines extended follow-up data from the ALPINE trial, emphasizing noteworthy findings from the sensitivity and safety analyses recently presented at ASH 2023.

Alessandra Ferrajoli, MD, discusses the research needs for describing the risk of hypertension associated with the various BTK inhibitors, key findings from the cumulative review presented at the 2023 ASH Annual Meeting, and more.

An abstract presented at the 2023 American Society of Hematology Annual Meeting and Exposition suggests that patients with chronic lymphocytic leukemia (CLL) treated in the era of novel agents might be less likely to experience Richter transformation compared with those treated prior to this era.

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for this population alongside the unmet needs it may address, highlights the efficacy and notable toxicities seen with the agent in the BRUIN study, and expands on the continued investigation of pirtobrutinib vs other standard-of-care regimens in various CLL subtypes.

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Comprehensive insights on clinical and patient factors that inform treatment selection and sequencing for patients with B-cell malignancies.